Information on the total number of voting rights and shares
25 Febbraio 2021 - 06:00PM
Information on the total number of voting rights and shares
PRESS RELEASE REGULATED
INFOMATION
Information on the total number of voting
rights and shares
Mont-Saint-Guibert (Belgium), 25
February 2021, 18:00h CET – In accordance with article 15
of the Law of 2 May 2007 on the disclosure of large shareholdings,
Nyxoah SA (Euronext: NYXH) publishes the below
information following the issue of 10,000 new shares on
22 February 2021 pursuant to the exercise of subscription
rights.
- Share capital: EUR 3,797,765.64
- Total number of securities carrying voting rights: 22,107,609
(all ordinary shares)
- Total number of voting rights (= denominator): 22,107,609 (all
relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting
rights not yet issued:
- 141 “2013 ESOP Warrants” issued on 3 May 2013 and 23 December
2014, entitling their holders to subscribe to a total number of
70,500 securities carrying voting rights (all ordinary
shares);
- 435 “2016 ESOP Warrants” issued on 3 November 2016, entitling
their holders to subscribe to a total number of 217,500 securities
carrying voting rights (all ordinary shares);
- 319 “2018 ESOP Warrants” issued on 12 December 2018, entitling
their holders to subscribe to a total number of 159,500 securities
carrying voting rights (all ordinary shares); and
- 550,000 “2020 ESOP Warrants” issued on 21 February 2020,
entitling their holders to subscribe to a total number of 550,000
securities carrying voting rights (all ordinary shares).
*
* *
- Ends -
For further information, please
contact:
NyxoahFabian Suarez,
CFOcorporate@nyxoah.com+32 (0)10 22 24 55
About Nyxoah
Nyxoah is a healthtech company focused on the
development and commercialization of innovative solutions and
services to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead
solution is the Genio® system, a CE-validated, patient-centered,
next generation hypoglossal neurostimulation therapy for OSA, the
world’s most common sleep disordered breathing condition that is
associated with increased mortality risk1 and comorbidities
including cardiovascular diseases, depression and stroke.
Following successful completion of the BLAST OSA
study in patients with moderate to severe OSA, the Genio® system
received its European CE Mark in March 2019. The Company is
currently conducting the BETTER SLEEP study in Australia and New
Zealand for therapy indication expansion, and a post-marketing
EliSA study in Europe to confirm the long-term safety and efficacy
of the Genio® system.
For more information, please visit
www.nyxoah.com.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
1 Young T. et al: Sleep Disordered Breathing and Mortality:
Eighteen-Year Follow-up of the Wisconsin Sleep Cohort, Sleep. 2008
Aug 1; 31(8): 1071–1078.
- 2021 02 25- Press release - Number of shares
Grafico Azioni Nyxoah (EU:NYXH)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Nyxoah (EU:NYXH)
Storico
Da Mar 2023 a Mar 2024